← Royalty Pharma plc
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | $246.2m | $1.0b | $1.5b | $1.7b | $477.0m | $929.0m | $618.7m | |
| Other royalty income receivable | $5.2m | $6.0m | $15.0m | $19.8m | $22.4m | $27.0m | $29.3m | |
| Other current assets | $92k | $8.6m | $6.6m | $90.5m | $3.8m | $4.2m | $6.9m | |
| Total current assets | $832.1m | $2.7b | $2.9b | $2.6b | $1.3b | $1.8b | $1.5b | |
| Goodwill | — | — | — | — | — | $0 | $924.6m | |
| Other assets | $45.6m | $23.2m | $4.1m | $29.6m | $6.5m | $33.5m | $79.3m | |
| Financial royalty assets | $452.6m | $587.2m | $614.4m | $691.3m | $738.4m | $783.8m | $854.4m | |
| Available for sale debt securities | $131.3m | $144.4m | $204.4m | $226.3m | $437.1m | $693.5m | $419.0m | |
| Financial royalty assets, net | $10.8b | $12.4b | $13.7b | $13.5b | $14.1b | $15.1b | $16.2b | |
| Equity securities | $380.8m | $298.7m | $269.8m | $112.3m | $199.5m | $187.0m | $171.3m | |
| Equity method investments | $124.1m | $454.9m | $435.4m | $397.2m | $375.9m | $379.4m | $290.0m | |
| Distributions payable to legacy non-controlling interests | — | — | $107.9m | $94.8m | $83.2m | $75.8m | $72.8m | |
| Interest payable | $0 | $42.1m | $57.7m | $54.2m | $51.7m | $98.1m | $110.8m | |
| Other current liabilities | — | $18.6m | $0 | $12.4m | $11.4m | $68.6m | $53.2m | |
| Other liabilities | — | — | $0 | $2.5m | $900k | $12.1m | $120.8m | |
| Deferred shares, $0.000001 par value; issued and outstanding: 2025–411,475 and 2024–392,255 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Non-controlling interests | $35.9m | $5.1b | $4.5b | $3.9b | $3.6b | $3.4b | $3.2b | |
| Treasury interests | ($4.3m) | ($2.3m) | ($2.7m) | ($2.8m) | ($2.6m) | ($2.7m) | ($2.6m) | |
| Total shareholders’ equity | $6.1b | $9.9b | $10.2b | $9.5b | $10.1b | $10.3b | $9.7b | |
| Total assets | $12.4b | $16.0b | $17.5b | $16.8b | $16.4b | $18.2b | $19.6b | |
| Accounts payable and accrued expenses | $11.2m | $10.8m | $5.6m | $7.9m | $15.2m | $13.4m | $19.4m | |
| Current portion of long-term debt | $282.0m | $0 | $0 | $997.5m | $0 | $997.8m | $380.0m | |
| Accrued compensation liabilities | — | — | — | — | — | $0 | $577.9m | |
| Total current liabilities | $333.4m | $307.9m | $171.2m | $1.2b | $161.4m | $1.3b | $636.2m | |
| Long-term debt | $6.0b | $5.8b | $7.1b | $6.1b | $6.1b | $6.6b | $8.6b | |
| Total liabilities | $6.3b | $6.1b | $7.3b | $7.3b | $6.3b | $7.9b | $9.9b | |
| Common stock | $0 | $102k | $106k | $107k | $108k | $108k | $106k | |
| Additional paid-in capital | $0 | $2.9b | $3.5b | $3.7b | $4.0b | $4.1b | $4.1b | |
| Retained earnings | $2.8b | $1.9b | $2.3b | $2.0b | $2.5b | $2.8b | $2.4b | |
| Total liabilities and shareholders’ equity | $12.4b | $16.0b | $17.5b | $16.8b | $16.4b | $18.2b | $19.6b |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.